Full-Time

Clinical Research Associate

Confirmed live in the last 24 hours

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using genetics

No salary listed

Senior

Boston, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Google Cloud Platform
Requirements
  • Bachelor's degree required with 6 years industry experience in clinical trials
  • At least 3 years’ monitoring experience
  • At least 2 years’ oncology monitoring experience
  • Experience supporting multiple complicated oncology studies simultaneously
  • Proven ability to develop relationships with investigator sites and vendors
  • Excellent working knowledge of ICH/GCP and relevant regulations
  • High attention to detail with a focus on quality and compliance in all aspects
  • Ability to travel as needed, up to 50%
  • Experience with Microsoft Office suite, EDC, CTMS, eTMF and other technologies
Responsibilities
  • Partner with our full service CRO in their contracted monitoring of our trials, ensuring compliance, data currency and relationship maintenance with sites
  • Conduct site visits to determine protocol and regulatory compliance, and prepare and maintain required documentation
  • Develop collaborative relationships with sites and study vendors
  • Provide support to the clinical study manager, assist with monitoring visit report review and other aspects
  • Develop study-specific monitoring tools to be used by the monitoring team to assist with study data review
  • Track enrollment status reports to ensure study sites stay on track to meet enrollment goals
  • Provide support for study sites with audits/inspections and preparation/responses and quality issues as needed
  • Review outstanding data reports to ensure data collection timelines are met
  • Perform Serious Adverse Event reconciliation and work with study sites to resolve discrepancies
  • Collaborate with others in a mutually supportive and cooperative manner assisting others when possible, to achieve study and project goals
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers like hospitals and cancer treatment centers, as well as pharmaceutical companies seeking advanced cancer therapies. They collaborate with larger pharmaceutical firms, such as Gilead Sciences, to co-develop new drugs, which helps them secure funding and speed up the development process. Tango's goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in synthetic lethality enhances Tango's innovative approach in oncology.
  • Recent $80 million financing strengthens Tango's financial position for future developments.
  • FDA clearance for TNG348 and TNG462 boosts Tango's clinical trial advancements.

What critics are saying

  • Discontinuation of TNG348 due to liver toxicity may affect investor confidence.
  • Reliance on partnerships for financial support poses risks if partnerships change.
  • Intensifying competition in precision oncology could impact Tango's market share.

What makes Tango Therapeutics unique

  • Tango leverages synthetic lethality to target cancer cells while sparing healthy ones.
  • Their focus includes counteracting tumor suppressor gene loss and immune evasion.
  • Strategic collaborations with pharma companies accelerate development and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Business Wire
May 23rd, 2024
Tango Therapeutics Announces Discontinuation Of Tng348 Program

BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.”

BioSpace
Mar 18th, 2024
Tango Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Highlights

BOSTON--(BUSINESS WIRE)-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.“In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials. These treatments have the potential to reach people with a wide range of cancers, including those with MTAP-deleted solid tumors, STK11 loss-of-function mutations, BRCA 1/2 mutations and other DNA damage repair defects. To support the advancement of our broad clinical portfolio, we expanded our management team, adding members with expertise in regulatory affairs and clinical development,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “We are off to a strong start in 2024, marked by dosing the first patient in the phase 1/2 clinical trial for TNG348, receiving Orphan Drug Designation from the U.S. FDA for TNG462 and strengthening our cash position

Business Wire
Mar 6th, 2024
Tango Therapeutics To Participate In Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.Leerink Partners 2024 Global Biopharma ConferenceDate: Tuesday, March 12, 2024Time: 3:00 PM ETLocation: Miami, FLBarclays 26th Annual Global Healthcare ConferenceDate: Wednesday, March 13, 2024Time: 9:30 AM ETLocation: Miami, FLA live webcast of the presentations will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcasts will be archived on the Company's website for 90 days following the presentation.About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com

BioSpace
Sep 18th, 2023
Tango Therapeutics To Highlight Preclinical Data On Precision Oncology Pipeline At Aacr-Nci-Eortc International Conference On Molecular Targets And Cancer Therapeutics

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.Abstracts accepted for poster presentationTitle: MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologies. Poster #: B018. Presenter: Matthew R. Tonini, Senior Scientist, Tango Therapeutics

Cision
Sep 11th, 2023
Medivir´S Partner Tango Therapeutics Received Fda Clearance To Start The Tng348 Phase 1/2 Clinical Study

Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study. .